AEON vs. LTRN, CLNN, LVTX, TELO, KZR, RNTX, KALA, OKUR, ESLA, and BDRX
Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Lantern Pharma (LTRN), Clene (CLNN), LAVA Therapeutics (LVTX), Telomir Pharmaceuticals (TELO), Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), KALA BIO (KALA), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry.
AEON Biopharma vs. Its Competitors
AEON Biopharma (NASDAQ:AEON) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.
Lantern Pharma is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
AEON Biopharma's return on equity of 0.00% beat Lantern Pharma's return on equity.
AEON Biopharma has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
AEON Biopharma presently has a consensus price target of $360.00, indicating a potential upside of 42,757.14%. Lantern Pharma has a consensus price target of $25.00, indicating a potential upside of 579.35%. Given AEON Biopharma's higher probable upside, research analysts clearly believe AEON Biopharma is more favorable than Lantern Pharma.
In the previous week, Lantern Pharma had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Lantern Pharma and 1 mentions for AEON Biopharma. Lantern Pharma's average media sentiment score of 0.94 beat AEON Biopharma's score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the news media.
22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 0.9% of AEON Biopharma shares are held by insiders. Comparatively, 7.3% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Lantern Pharma beats AEON Biopharma on 7 of the 11 factors compared between the two stocks.
Get AEON Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AEON Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:AEON) was last updated on 7/12/2025 by MarketBeat.com Staff
